• Jasper Therapeutics completed IgA nephropathy enrollment in its Phase 2 renal basket trial of vensobafusp alfa (KP104), enrolling 18 patients.
• Initial interim results are expected by year-end 2026 to assess safety, tolerability and early efficacy.
• An accelerated expansion into focal segmental glomerulosclerosis targets first patient dosing in the first quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jasper Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-109587), on October 15, 2026, and is solely responsible for the information contained therein.